Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HZN-825 in Idiopathic Pulmonary Fibrosis
NCT05032066Phase 2Terminated
- Sponsor
- Amgen
- Start
- Jan 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 2 trial of fipaxalparant in idiopathic pulmonary fibrosis (IPF), sponsored by Amgen. Started Jan 2022; status: terminated.
02
Drugs
fipaxalparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05032066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05032066.